Alpha Profiles · Company Profile

Lakefront Biotherapeutics NV

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies.

https://registry.alpha.ac/companies/lakefront-biotherapeutics-nv

Entity: Public listing published
Primary listing: OTC: GLPGF
Verification: Partially verified
Last reviewed: 2026-10-27T04:48:04.401865+00:00

Overview

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 27, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

0 public records

Board roster coverage is NOT_ASSERTED. An empty list is not evidence that this company has no board.

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-10-27T04:48:04.401865+00:00